Incyte’s JAK inhibitor cream clears second eczema trial

Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... Incyte has said it intends to market ruxolitinib cream itself in

Novartis pulls ahead of Merck in MET-positive lung cancer race

Capmatinib – originally developed by Incyte and licensed to Novartis in 2009 – has been submitted for approval in the US for metastatic MET exon14 skipping-mutated NSCLC, a form of lung cancer

Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

to patients and the clinical community around the world,” said Hervé Hoppenot, CEO of Incyte. ... Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company.

Incyte claims FDA priority review for bile duct cancer drug

Significant need for new therapies in hard-to-treat cancer type. Incyte’s new drug pemigatinib has been given a priority review for a rare type of bile duct cancer by ... Incyte says cholangiocarcinoma affects between 0.3 – 3.4 people per 100, 000 in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]